Samsung Bioepis

August 29, 2017August 29, 2017

European Commission Approves Biosimilar Imraldi for Crohn’s Disease and Ulcerative Colitis

News

The European Commission has approved Imraldi, an adalimumab biosimilar referencing AbbVie’s Humira — making the medication available to treat the same therapeutic indications as Humira, including Crohn’s disease, pediatric Crohn’s disease and ... Read more

July 26, 2017August 18, 2017

Renflexis, a Remicade Biosimilar, Launched in US to Treat Crohn’s and UC

Crohn's Disease, News

New drug Renflexis (infliximab-abda), a therapy for ulcerative colitis and Crohn’s disease, is being launched in the U.S., South Korea’s Samsung Bioepis recently announced. Renflexis is a biosimilar of the anti-inflammatory ... Read more

June 26, 2017

EMA Committee Urges Approval of Humira Biosimilar Imraldi to Treat IBDs

News

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion regarding on marketing authorization for Imraldi (adalimumab), a biosimilar candidate referencing Humira. The EMA ... Read more

April 6, 2016April 6, 2016

CHMP Issues Positive Opinion on Samsung Bioepis’ Flixabi, a Biosimilar Treatment for IBD

Crohn's Disease, IBD News, News, Ulcerative colitis

The Committee for Medicinal Products for Human Use (CHMP), the scientific board of European Medicines Agency, has issued a positive opinion on Samsung Bioepis’ Flixabi for the treatment of ulcerative colitis (UC) ... Read more